Maria Palasis - 01 Oct 2025 Form 4/A - Amendment Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role: President & CEO, Director
Signature: /s/ Jason Cavalier, Attorney-in-Fact for Maria Palasis, Ph.D.
Issuer symbol: LYRA
Transactions as of: 01 Oct 2025
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 08 Oct 2025, 16:30:03 UTC
Date Of Original Report: 03 Oct 2025
Previous filing: 14 Jul 2025
Next filing: 05 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Palasis Maria	President & CEO, Director	C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN	/s/ Jason Cavalier, Attorney-in-Fact for Maria Palasis, Ph.D.	08 Oct 2025	0001810701

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LYRA	Employee Stock Option (right to buy)						0	01 Oct 2025	Common Stock	0	$303.50	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 21, 2024, the Reporting Person was granted a performance stock option ("PSO") for an aggregate of up to 11,000 shares of common stock (or 550,000 shares on a pre-split basis) under the Issuer's 2020 Incentive Award Plan. On February 14, 2025, the PSOs were forfeited in their entirety by the Reporting Person for no value.

Remarks:

On October 3, 2025, a Form 4 was inadvertently filed reporting the acquisition of 3,667 PSOs by the Reporting Person. In fact, the Reporting Person did not acquire the PSOs and this Form 4/A is being filed to correct the erroneously reported acquisition. As of the date hereof, the Reporting Person does not beneficially own any of the PSOs granted on March 21, 2024.